Table 1.
Baseline characteristics of entire cohort, according to the presence or absence of renal impairment (eGFR<60 mL/min)
| Overall | Baseline eGFR <60 mL/min/1.73 m2 |
p Value | ||
|---|---|---|---|---|
| (n=897) | No (n=639) | Yes (n=258) | ||
| Age (years) | 71.8±9.0 | 69.8±8.9 | 76.7±7.3 | <0.001 |
| Women (%) | 41.8 | 36.9 | 53.9 | <0.001 |
| Permanent AF (%) | 43.1 | 40.7 | 49.2 | 0.021 |
| Body mass index (kg/m2) | 27.9±4.6 | 28.1±4.6 | 27.7±4.5 | 0.300 |
| Ankle-Brachial Index ≤0.90 (%) | 21.6 | 16.6 | 34.1 | <0.001 |
| CHA2DS2-VASc score | 3.0 (2.0–4.0) | 3.0 (2.0–4.0) | 4.0 (3.0–5.0) | <0.001 |
| Arterial hypertension (%) | 86.3 | 85.4 | 88.4 | 0.284 |
| Diabetes mellitus (%) | 24.1 | 22.7 | 27.5 | 0.075 |
| History of MI/CHD (%) | 18.4 | 16.7 | 22.5 | 0.029 |
| Heart failure (%) | 19.0 | 16.4 | 25.2 | 0.003 |
| History of stroke/TIA (%) | 11.3 | 11.1 | 11.6 | 0.816 |
| ACE inhibitor/ARBs (%) | 72.8 | 71.4 | 76.4 | 0.074 |
| β blockers (%) | 48.6 | 47.1 | 52.3 | 0.090 |
| Calcium channel antagonists (%) | 27.2 | 26.0 | 30.2 | 0.195 |
| Statins (%) | 44.4 | 43.3 | 46.9 | 0.336 |
| Antiplatelets (%) | 19.6 | 20.5 | 17.4 | 0.309 |
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARBs, angiotensin receptor blockers; CHD, coronary heart disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; TIA, transient ischaemic attack.